Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE; Parkinson Study Group DATATOP Investigators.

Mov Disord. 2008 Apr 15;23(5):653-9; quiz 776.

PMID:
18076084
2.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
3.

Determinants of quality of life in Brazilian patients with Parkinson's disease.

Carod-Artal FJ, Vargas AP, Martinez-Martin P.

Mov Disord. 2007 Jul 30;22(10):1408-15.

PMID:
17516479
4.
5.

Predictors and course of health-related quality of life in Parkinson's disease.

Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G.

Mov Disord. 2008 Jul 30;23(10):1420-7. doi: 10.1002/mds.22121.

PMID:
18512757
6.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group.

Ann Neurol. 2002 May;51(5):604-12.

PMID:
12112107
7.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
8.

Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort.

Qin Z, Zhang L, Sun F, Liu H, Fang X, Chan P; Chinese Parkinson Study Group.

Clin Neurol Neurosurg. 2009 Nov;111(9):733-7. doi: 10.1016/j.clineuro.2009.07.001. Epub 2009 Aug 8.

PMID:
19665835
9.

Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group.

Neurology. 2005 Jan 11;64(1):87-93.

PMID:
15642909
10.
11.

The relative health related quality of life of veterans with Parkinson's disease.

Gage H, Hendricks A, Zhang S, Kazis L.

J Neurol Neurosurg Psychiatry. 2003 Feb;74(2):163-9.

12.

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, et al.

Neurology. 1994 Sep;44(9):1756-9.

PMID:
7936311
13.
14.
15.

The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis.

Unruh ML, Newman AB, Larive B, Dew MA, Miskulin DC, Greene T, Beddhu S, Rocco MV, Kusek JW, Meyer KB; Hemodialysis Study Group.

J Am Geriatr Soc. 2008 Sep;56(9):1608-17. doi: 10.1111/j.1532-5415.2008.01849.x. Epub 2008 Aug 21.

PMID:
18721224
16.

What contributes to depression in Parkinson's disease?

Schrag A, Jahanshahi M, Quinn NP.

Psychol Med. 2001 Jan;31(1):65-73.

PMID:
11200961
17.

What contributes to quality of life in patients with Parkinson's disease?

Schrag A, Jahanshahi M, Quinn N.

J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):308-12.

18.

Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease.

Karlsen KH, Larsen JP, Tandberg E, Maeland JG.

J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):431-5.

19.

Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

Vu TC, Nutt JG, Holford NH.

Br J Clin Pharmacol. 2012 Aug;74(2):284-95. doi: 10.1111/j.1365-2125.2012.04208.x.

20.

Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.

Dalrymple-Alford JC, Jamieson CF, Donaldson IM.

Clin Neuropharmacol. 1995 Aug;18(4):348-59.

PMID:
8665548

Supplemental Content

Support Center